药明生物(02269)公布2024年年报,实现营业收入186.8亿元人民币,非新冠收入同比增长13.1%,毛利和EBITDA分别增长12.1%和16.7%。尽管股价年初至今上涨47.49%,但仍低于各大投行的估价。摩根士丹利和中金公司相继上调其目标价至45港元和50港元,并给予正面评级。药明生物在全球CXO行业充满挑战的环境下,依然高分完成业绩指引,新签订单大增,分子项目和PPQ项目均超预期。公司...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.